Estimating the relative risk of developing melanoma in INK4A carriers

European Journal of Cancer Prevention

Volumn 13, Issue 1, 2004, Pages 65-70

  Berwick, M ^a,d   Orlow, I ^a   Mahabir, S ^a   Myskowski, P ^a   Coit, D ^b   Brady, M S ^b   Roy, P ^a   Song, Y ^a   Canchola, R ^a   Barz, A ^a   Halpern, A ^a   Bolognia, J ^c   Eng, S ^a   Elahi, A ^a   Begg, C B ^a  

^a Dept of Epidemiol and Biostatist ^*  (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF NEW MEXICO   (United States)

Author keywords

INK4A; Melanoma; Relative risk

Indexed keywords

CYCLIN DEPENDENT KINASE 4 INHIBITOR; CYCLIN DEPENDENT KINASE INHIBITOR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER RISK; CONTROLLED STUDY; EYE COLOR; FEMALE; GENE MUTATION; HAIR COLOR; HETEROZYGOTE; HUMAN; MALE; MELANOMA; MULTIPLE CANCER; PHENOTYPE; PILOT STUDY; PRIORITY JOURNAL; QUESTIONNAIRE; RISK ASSESSMENT; RISK FACTOR; SKIN COLOR;

ADOLESCENT; ADULT; CASE-CONTROL STUDIES; CHROMATOGRAPHY, LIQUID; CYCLIN-DEPENDENT KINASE INHIBITOR P16; FEMALE; GERM-LINE MUTATION; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEOPLASMS, MULTIPLE PRIMARY; NEVUS; NUCLEIC ACID DENATURATION; ODDS RATIO; PILOT PROJECTS; POLYMERASE CHAIN REACTION; PREVALENCE; QUESTIONNAIRES; RISK FACTORS; SKIN NEOPLASMS;

EID: 12144288315     PISSN: 09598278     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008469-200402000-00010     Document Type: Article

References (29)

1. Aitken J, Welch J, Duffy D, et al. (1999). CDKN2A variants in a population-based sample of Queensland families with melanoma. J National Cancer Institute 91: 446-452.
2. Auroy S, Avril M-F, Compret A, et al. and the French Hereditary Melanoma Study Group, Bressac-de Paillerets B (2001). Sporadic multiple primary melanoma cases: CDKN2A germline mutations with a founder effect. Genes Chromos Cancer 32: 195-201.
3. Begg CB, Berwick M (1997). A note on the estimation of relative risks of rare genetic susceptibility markers. Cancer Epidemiol Biomarkers Prev 6: 99-103.
4. Begg CB, Gray R (1987). Methodology for case-control studies with prevalent cases. Biometrika 74: 191-195.
5. Berwick M, Begg CB, Fine JA, Roush GC, Barnhill RL (1996). Screening for malignant melanoma by skin self-examination. J Natl Cancer Inst 88: 17-23.
6. Borg A, Johansson U, Johansson O, et al. (1996). Novel germline p16 mutation in familial malignant melanoma in southern Sweden. Cancer Res 56: 2497-2500.
7. Burden AD, Newell J, Andrew N, et al. (1999). Genetic and environmental influences in the development of multiple primary melanoma. Arch Dermatol 135: 261-265.
8. Ciotti P, Struewing JP, Mantelli M, et al. (2000). A single genetic origin for the G101W CDKN2A mutation in 20 melanoma-prone families. Am J Hum Genet 67: 311-319.
9. ARF, and CDK4 in familial melanoma: analysis of a clinic-based population. Proc Natl Acad Sci USA 93: 8541-8545.
10. Harland M, Meloni R, Gruis N, et al. (1997). Germline mutations of the CDKN2 gene in UK melanoma families. Hum Mol Genet 6: 2061-2067.
11. Hashemi J, Platz A, Ueno T, et al. (2000). CDKN2A Germ-line mutations in individuals with multiple cutaneous melanomas. Cancer Res 60: 6864-6847.
12. Holland EA, Beaton SC, Becker TM, et al. (1995). Analysis of the p16 gene, CDKN2, in 17 Australian kindreds. Oncogene 11: 2289-2294.
13. INK4a) and CDK4 mutation analysis in 131 Australian melanoma probands: effect of family history and multiple primary melanomas. Genes Chromos Cancer 25: 339-348.
14. Hussussian CJ, Struewing JP, Goldstein AM, et al. (1994). Germline p16 mutations in familial melanoma. Nature Genet 8: 15-21.
15. Kamb A, Gruis NA, Weaver-Feldhaus J, et al. (1994). A cell cycle regulator potentially involved in genesis of many tumor types. Science 264: 436-440.
16. MacKie RM, Andrew N, Lanyon WG, Connor JM (1998). CDKN2A germline mutations in UK patients with familial melanoma and multiple primary melanomas. J Investig Dermatol 111: 269-272.
17. Monzon J, Liu L, Brill H, et al. (1998). CDKN2A mutations in multiple primary melanomas. N Engl J Med 338: 879-887.
18. Orlow I, Roy P, Barz A, et al. (2001). Validation of a rapid detection method - denaturing high performance liquid chromatography (DHPLC) for the identification of human INK4A gene mutations. J Mol Diagn 3: 158-163.
19. Ranade K, Hussussian CJ, Sikorski RS, et al. (1995). Mutations associated with familial melanoma impair p16INK4 function. Nature Genet 10: 114-116.
20. Reymond A, Brent R (1995). p16 proteins from melanoma-prone families are deficient in binding to Cdk 4. Oncogene 11: 1173-1178.
21. Richards B, Skoletsky J, Shuber AP, et al. (1993). Multiplex PCR amplification from the CFTR gene using DNA prepared from buccal swabs/brushes. Hum Mol Genet 2: 159-163.
22. Ruiz A, Puig S, Malvehy J, et al. (1999). CDKN2A mutations in Spanish cutaneous malignant melanoma families and patients with multiple melanomas and other neoplasia. J Med Genet 36: 490-493.
23. Serrano M, Hannon GJ, Beach D (1993). A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366: 704-707.
24. Soufir N, Avril MF, Compret A, et al. (1998). Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. The French Familial Melanoma Study Group. Hum Mol Genet 7: 209-216.
25. Walker GJ, Hussussian CJ, Flores JF, et al. (1995). Mutations of the CDKN2/p16 (INK4) gene in Australian melanoma kindreds. Hum Mol Genet 4: 1845-1852.
26. Whelan AJ, Bartsch D, Goodfellow PJ (1995). A familial syndrome of pancreatic cancer and melanoma with a mutation in the CDKN2 tumor-suppressor gene. N Engl J Med 333: 975-977.
27. Yakobson E, Shemesh P, Azizi E, et al. (2000). Two p16 (CDKN2A) germline mutations in 30 Israeli melanoma families. Eur J Hum Genet 8: 590-596.
28. Yang R, Serrano M, Slater J, Leung E, Koeffler HP (1996). Analysis of p16INK4a and its interaction with CDK4. Biochem Biophys Res Commun 218: 254-259.
29. Zuo L, Weger J, Yang Q, et al. (1996). Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nature Genet 12: 97-99.